The National Heart, Lung, and Blood Institute (NHLBI) of the US National Institutes of Health (NIH) has opted to pause the CONCERT-HF trial involving patients with chronic heart failure.

The decision is a result of recent calls for the withdrawal of journal articles in the fields of cell therapy research. The calls have also raised concerns about the scientific foundations of the CONCERT-HF trial.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Though the articles are not related to the Phase II trial, NHLBI intends to put the trial on hold to ensure the highest standards of safety for the participants and maintain scientific integrity.

Following the decision, CONCERT-HF’s Data and Safety Monitoring Board (DSMB) will be able to complete its review and will inform NHLBI’s future actions regarding the trial.

“NHLBI intends to put the trial on hold to ensure the highest standards of safety for the participants and maintain scientific integrity.”

CONCERT-HF was designed to evaluate the feasibility, safety, and effect of autologous bone marrow-derived mesenchymal stem cells (MSCs) and c-kit+ cardiac stem cells (CSCs) both alone and in combination, compared to placebo (cell-free Plasmalyte-A medium), as well as each other, in subjects with heart failure of ischemic etiology.

The randomised, placebo-controlled, parallel assignment trial would have enrolled 144 participants.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial was designed to include a lead-in phase, with participants then been randomised in 1:1:1:1 ratio to receive the trial’s combination therapy, MSCs, CSCs, or placebo.

Investigators of the trial were planning to use an ‘intention-to-treat’ study population to conduct endpoint analysis and safety evaluations.

The primary endpoint of CONCERT-HF included changes in left ventricular ejection fraction (LVEF), in global strain (HARP MRI) and in regional strain (HARP MRI).